+44 115 7870500
DevelRx Logo
HomeTeam
Services
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact

David Heal will be giving a lecture at a Continuing Education Course, “Understanding the Assessment of Abuse Potential: Industry and Regulatory Perspective,” American College of Toxicology (Virtual) 15th – 18th November.

Back to News & Events

David will be joined by other experts in the field including Ed Sellers, Michael Klein (former Director of the Controlled Substance Staff [CSS] at the FDA) and Dominic Chiapperino (current Director of CSS).

Session Chairs: Reem Elbekai, Otsuka Pharmaceutical Development and Commercialization, Rockville, MD; and William Brock, Brock Scientific Consulting, LLC, Montgomery Village, MD.

Pharmacology and Molecular Mechanisms of Drugs of Abuse

Michael Klein, Controlled Substance Scientific Solutions, LLC, Chevy Chase, MD

Building the Nonclinical Study Package to Address Abuse Potential

David Heal, DevelRx Ltd, Nottingham and University of Bath, United Kingdom

Conducting a Successful Human Abuse Potential Study and Leveraging Data from Other Clinical Trials

Edward Sellers, University of Toronto and DL Global Partners Inc, Toronto, ON, Canada

The US FDA’s Role in Drug Scheduling and the Eight Factor Analysis

Dominic Chiapperino, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD

DevelRx Logo

Biocity,

Pennyfoot Street,

Nottingham,

Nottinghamshire,

NG1 1GF

Legal

Cookie PolicyPrivacy PolicyTerms & Conditions
inform@develrx.com

Registered in England and Wales

Company number: 12028847